"Certolizumab Pegol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A polyethylene-glycolated Fab' fragment of TUMOR NECROSIS FACTOR antibody that binds specifically to TNF-ALPHA and neutralises it in a dose-dependent manner. It also inhibits the production of lipopolysaccharide-induced TNF-ALPHA and IL-1 BETA and is used to treat RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
| Descriptor ID |
D000068582
|
| MeSH Number(s) |
D05.750.741.125 D12.644.541.500.650.250 D12.776.124.486.485.114.224.060.500 D12.776.124.486.485.680.650.250 D12.776.124.790.651.114.224.060.500 D12.776.124.790.651.680.650.250 D12.776.377.715.548.114.224.200.500 D12.776.377.715.548.680.650.250
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Certolizumab Pegol".
- Chemicals and Drugs [D]
- Macromolecular Substances [D05]
- Polymers [D05.750]
- Polyethylene Glycols [D05.750.741]
- Certolizumab Pegol [D05.750.741.125]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Peptide Fragments [D12.644.541]
- Immunoglobulin Fragments [D12.644.541.500]
- Immunoglobulin Fab Fragments [D12.644.541.500.650]
- Certolizumab Pegol [D12.644.541.500.650.250]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Certolizumab Pegol [D12.776.124.486.485.114.224.060.500]
- Immunoglobulin Fragments [D12.776.124.486.485.680]
- Immunoglobulin Fab Fragments [D12.776.124.486.485.680.650]
- Certolizumab Pegol [D12.776.124.486.485.680.650.250]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Certolizumab Pegol [D12.776.124.790.651.114.224.060.500]
- Immunoglobulin Fragments [D12.776.124.790.651.680]
- Immunoglobulin Fab Fragments [D12.776.124.790.651.680.650]
- Certolizumab Pegol [D12.776.124.790.651.680.650.250]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Certolizumab Pegol [D12.776.377.715.548.114.224.200.500]
- Immunoglobulin Fragments [D12.776.377.715.548.680]
- Immunoglobulin Fab Fragments [D12.776.377.715.548.680.650]
- Certolizumab Pegol [D12.776.377.715.548.680.650.250]
Below are MeSH descriptors whose meaning is more specific than "Certolizumab Pegol".
This graph shows the total number of publications written about "Certolizumab Pegol" by people in this website by year, and whether "Certolizumab Pegol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 5 | 5 |
| 2011 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Certolizumab Pegol" by people in Profiles.
-
Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). Br J Dermatol. 2021 04; 184(4):652-662.
-
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072.
-
Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Inflamm Bowel Dis. 2016 08; 22(8):1870-80.
-
Incidence and predictors of clinical response, re-induction dose, and maintenance dose escalation with certolizumab pegol in Crohn's disease. Inflamm Bowel Dis. 2014 Oct; 20(10):1722-8.
-
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013 Mar; 11(3):286-92; quiz e24.
-
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-a) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013 Jan; 108(1):99-105.
-
Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis. 2012 Dec; 18(12):2225-31.
-
Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol. Aliment Pharmacol Ther. 2011 May; 33(10):1143-51.
-
Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. Aliment Pharmacol Ther. 2011 Jan; 33(2):185-93.
-
The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol. 2011 Feb; 106(2):199-212; quiz 213.